Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 54)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Immunoglobulin G |
|
Phase 4 |
|
|
|
| 2 |
|
Glycine |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
56-40-6 |
750 |
|
Synonyms:
[<sup>14</sup>C]-glycine
2-Aminoacetate
2-Aminoacetic acid
Acid, aminoacetic
Aciport
Aminoacetate
Amino-acetate
Amino-acetic acid
AMINOACETIC ACID
AMINOESSIGSAEURE
AMINOESSIGSÄURE
Aminoethanoate
AMINOETHANOIC ACID
Calcium salt glycine
Cobalt salt glycine
Copper salt glycine
FEMA NO. 3287
G
Glicina
Glicoamin
GLY
GLYCIN
GLYCINE
Glycine carbonate (1:1), monosodium salt
Glycine carbonate (2:1), monolithium salt
Glycine carbonate (2:1), monopotassium salt
Glycine carbonate (2:1), monosodium salt
Glycine hydrochloride
Glycine hydrochloride (2:1)
Glycine phosphate
|
Glycine phosphate (1:1)
Glycine sulfate (3:1)
Glycine, calcium salt
Glycine, calcium salt (2:1)
Glycine, cobalt salt
Glycine, copper salt
Glycine, monoammonium salt
Glycine, monopotasssium salt
Glycine, monosodium salt
Glycine, sodium hydrogen carbonate
GLYCOCOLL
GLYCOLIXIR
Glycosthene
GLYKOKOLL
GLYZIN
Gyn-hydralin
H2N-CH2-COOH
HGLY
Hydrochloride, glycine
LEIMZUCKER
Monoammonium salt glycine
Monopotasssium salt glycine
Monosodium salt glycine
NSC-25936
Padil
Phosphate, glycine
Salt glycine, monoammonium
Salt glycine, monosodium
جلايسين
|
|
| 3 |
|
Immunoglobulins, Intravenous |
|
Phase 3 |
|
|
|
| 4 |
|
Immunoglobulins |
|
Phase 3 |
|
|
|
| 5 |
|
Antibodies |
|
Phase 3 |
|
|
|
| 6 |
|
gamma-Globulins |
|
Phase 3 |
|
|
|
| 7 |
|
Rho(D) Immune Globulin |
|
Phase 3 |
|
|
|
| 8 |
|
Prednisone |
Approved, Vet_approved |
Phase 2 |
|
53-03-2 |
5865 |
|
Synonyms:
1,2-Dehydrocortisone
1,4-Pregnadiene-17a,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17α,21-diol-3,11,20-trione
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
Acis brand OF prednisone
Acsis, prednison
Adasone
Ancortone
Apo-prednisone
Apotex brand OF prednisone
Aventis brand OF prednisone
Betapar
Bicortone
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
Cutason
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta-cortelan
Deltacortene
delta-Cortisone
Deltacortisone
Deltacortone
Delta-cortone
DELTA-DOME
Deltasone
Deltison
Deltisona
Deltisone
Deltra
Diadreson
Di-Adreson
Diba brand OF prednisone
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fawns and mcallan brand OF prednisone
FERNISONE
Ferring brand OF prednisone
Fiasone
GALENpharma brand OF prednisone
Halsey drug brand OF prednisone
Hexal brand OF prednisone
Hoechst brand OF prednisone
Hostacortin
ICN brand OF prednisone
Incocortyl
In-Sone
Juvason
Kortancyl
Lichtenstein brand OF prednisone
|
Liquid pred
Lisacort
LODOTRA
Lodotra®|Sterapred®
Me-Korti
Merck brand OF prednisone
Merz brand OF prednisone
Metacortandracin
Meticorten
Mibe brand OF prednisone
Nisona
Nizon
Novoprednisone
NSC-10023
Nurison
Orasone
Origen Prednisone
Panafcort
Panasol
PARACORT
Parmenison
Pehacort
Pharmacia brand OF prednisone
PRD
Precort
Predeltin
PREDN
Predni tablinen
PREDNICEN-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Predniment
Prednison
Prednison acsis
Prednison galen
Prednison hexal
Prednisona
Prednisona [INN-Spanish]
Prednisone
PREDNISONE INTENSOL
PREDNISONE TABLETS
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Pronison
Pronisone
RAYOS
Rectodelt
Retrocortine
Schering-plough brand OF prednisone
Seatrace brand OF prednisone
SERVISONE
Solvay brand OF prednisone
Sone
Sterapred
Supercortil
Trommsdorff brand OF prednisone
Ultracorten
Ultracortene
Winpred
Wojtab
Zenadrid
|
|
| 9 |
|
Melphalan |
Approved |
Phase 2 |
|
148-82-3 |
4053 460612 |
|
Synonyms:
2-Amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate
2-Amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoate
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
AIKERAN
ALANINE NITROGEN MUSTARD
Alkeran
CB-3025
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
L-PAM
L-Phenylalanine mustard
L-PHENYLALANINE MUSTARD (L-PAM)
L-SARCOLYSIN
L-Sarcolysine
L-Sarkolysin
Medphalan
MELFALAN
Melfalano
Melphalan
|
Melphalanum
Mephalan
Merphalan
MLP673
Mustard, phenylalanine
NCI-C04853
NSC-241286
NSC-8806
p-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
p-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
Sarcolysin
Sarcolysine
Sarkolysin
SK 15673
SK-15673
|
|
| 10 |
|
Carmustine |
Approved, Investigational |
Phase 2 |
|
154-93-8 |
2578 |
|
Synonyms:
1,3-Bis(2-chloroethyl)-1-nitrosourea
BCNU
Bicnu
BICNU (TN)
Bischlorethylnitrosourea
Bischlorethylnitrosurea
Bischloroethyl nitrosourea
BIS-CHLOROETHYLNITROSOUREA
Carmustin
Carmustina
CARMUSTINE
|
Carmustinum
CARUSTINE
DTI-015
FDA-0345
FIVB
Gliadel
N,N'-bis(2-chloroethyl)-N-nitrosourea
Nitrumon
NSC-409962
SK-27702
SRI-1720
|
|
| 11 |
|
Etoposide |
Approved |
Phase 2 |
|
33419-42-0 |
36462 |
|
Synonyms:
(-)-Etoposide
(−)-ETOPOSIDE
(-)-etoposide|Etopophos®|Toposar®|trans-etoposide|VePesid®|VP 16-213|VP-16
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
alpha-D-Glucopyranosyl isomer etoposide
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
Celltop
Demethyl epipodophyllotoxin ethylidine glucoside
Eposide
Eposin
Eto gry
Eto-gry
Etomedac
Etopophos
Etopos
ETOPOSIDE
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
|
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
Lastet
Lemery brand OF etoposide
Medac brand OF etoposide
Novartis brand OF etoposide
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Riboposid
Ribosepharm brand OF etoposide
Sanfer brand OF etoposide
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Teva, etoposide
Toposar
trans-Etoposide
Vepesid
Vepesid J
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16-213
VP-16
VP-16-213
Zuyeyidal
|
|
| 12 |
|
Picropodophyllin |
Approved, Investigational |
Phase 2 |
|
518-28-5, 477-47-4 |
10607 72435 |
|
Synonyms:
(−)-podophyllotoxin
(-)-Podophyllotoxin
6,7]NAPHTHO[2,3-D][1,3]DIOXOL-6(5AH)-ONE
9-HYDROXY-5-(3,4,5-TRIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDROFURO[3',4'
9-HYDROXY-5-(3,4,5-trimethoxyphenyl)-5,8,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-D][1,3]dioxol-6(5ah)-one
Ardern brand OF podophyllotoxin
AXL-1717
AXL1717|podofilox
Canderm brand OF podophyllotoxin
Condyline
Condylox
CPH86
Epipodophyllotoxin
Fides ecopharma brand OF podophyllotoxin
Hamilton brand OF podophyllotoxin
Newport brand OF podophyllotoxin
NSC-24818
NSC-36407
Oclassen brand OF podophyllotoxin
Paddock brand OF podophyllotoxin
Paladin brand OF podophyllotoxin
|
PICROPODOPHYLLIN
PICROPODOPHYLLOTOXIN
PODOCON-25
Podofilm
Podofilox
Podophyllinate lactone
Podophyllinic acid lactone
Podophyllotoxin
Podophyllotoxin 7
PODOPHYLLOTOXIN PICROPODOPHYLLIN
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a alpha,9 beta))-isomer
Podophyllotoxin, (5R-(5 alpha,5a alpha,8a beta,9 alpha))-isomer
Podophyllotoxin, (5R-(5 alpha,5a beta,8a alpha,9 beta))-isomer
PPT
Stiefel brand OF podophyllotoxin
Wartec
Warticon
Wolff brand OF podophyllotoxin
Yamanouchi brand OF podophyllotoxin
|
|
| 13 |
|
Cytarabine |
Approved, Investigational |
Phase 2 |
|
147-94-4 |
6253 |
|
Synonyms:
(beta-D-Arabinofuranosyl)cytosine
1-Arabinofuranosylcytosine
1-b-D-Arabinofuranosylcytosine
1beta -Arabinofuranasylcytosine
1-beta -D-Arabinofaranosylcytosine
1-beta -D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta -D-Arabinofuranosylcytosine
1-beta -D-Arabinofuranosylcytosine
1beta -D-Arabinosylcytosine
1beta-Arabinofuranasylcytosine
1-beta-D-Arabinofaranosylcytosine
1-beta-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone
1beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosylcytosine
1-beta-D-Arabinofuranosyl-cytosine
1-beta-D-Arabinofuranosylcytosine, cytosine arabinoside
1beta-D-Arabinosylcytosine
1-beta-D-Arabinosylcytosine
1-beta-D-Arabinosyl-cytosine
1-Î’-D-arabinofuranosylcytosine
2(1H)-Pyrimidinone, 4-amino-1- -D-arabinofuranosyl
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidin
4-Amino-1-arabinofuranosyl-2-oxo-1,2-dihydropyrimidine
4-Amino-1-b-D-arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-b-D-arabinofuranosyl-2-(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone
4-Amino-1-beta-D-arabinofuranosylpyrimidin-2(1H)-one
4-Amino-1-β-D-arabinofuranosyl-2(1H)-pyrimidinone
Alexan
ALEXAN 100
AR3
Ara C
Arabinocytidine
Arabinocytosine
Arabinofuranosylcytosine
Arabinoside C
Arabinoside, cytosine
ARABINOSYL CYTOSINE
Arabinosylcytosine
Arabitin
AraC
Ara-C
Aracytidine
ARA-CYTIDINE
Aracytin
Aracytine
Arafcyt
beta Ara C
beta -Arabinosylcytosine
beta -Cytosine arabinoside
beta -D-Arabinosylcytosine
beta-Ara c
|
beta-Arabinosylcytosine
beta-Cytosine arabinoside
beta-D-Arabinosylcytosine
Citarabina
Citarabina [INN-Spanish]
Cytarabin
Cytarabina
Cytarabine
Cytarabine hydrochloride
Cytarabine liposome
Cytarabine liposome injection
Cytarabinoside
Cytarabinum
Cytarabinum [INN-Latin]
Cytarbel
Cytonal
Cytosar
Cytosar u
Cytosar-u
CytosarU
Cytosine 1-beta-D-arabinofuranoside
Cytosine arabinofuranoside
Cytosine arabinose
Cytosine arabinoside
Cytosine beta-D-arabinofuranoside
Cytosine beta-D-arabinoside
Cytosine, beta -D-arabinoside
Cytosine, beta-D-arabinoside
Cytosine-1-b-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside
Cytosine-1-beta-D-arabinofuranoside hydrochloride
Cytosine-1-β-D-arabinofuranoside
Cytosinearabinoside
Cytosine-b-D-arabinofuranoside
Cytosine-beta -arabinoside
Cytosine-beta -D-arabinofuranoside
Cytosine-beta-arabinoside
Cytosine-beta-D-arabinofuranoside
Cytosine-β-D-arabinofuranoside
Depocyt
Depocyt (liposomal)
Depocyte
Erpalfa
Hydrochloride, cytarabine
Iretin
NSC-287459
Spongocytidine
Tarabine
TARABINE PFS
U-19920
Udicil
|
|
| 14 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2 |
|
51-75-2 |
4033 |
|
Synonyms:
2,2'-Dichloro-N-methyldiethylamine
b,Beta'-dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
BIS (2-CHLOROETHYL) METHYLAMINE
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
Caryolysine
Chlorethazine
Chlormethine
Chlormethinum
Cloramin
Clormetina
Embichin
HN2
HN-2
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
MBA
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechloroethamine
Mecloretamina
|
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Mitomen
Mustargen
Mustine
Nitrogen mustard
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE
Nitrogranulogen
Nitromin
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC-10107
NSC-128663
NSC-762
Î’,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
| 15 |
|
Rituximab |
Approved |
Phase 2 |
|
174722-31-7 |
|
|
Synonyms:
ABP-798
ANTICD20
CT-P10
HS006
HS-006
HS-006 (RITUXIMAB BIOSIMILAR)
HSDB 7455|IDEC-C2B8|MabThera®|Rituxan®
IDEC-102
IDEC-C2B8
IG GAMMA-1 CHAIN C REGION
Ig gamma-2A chain C region, membrane-bound form
MABTHERA
MABTHERA RITUXAN
|
R-105 IDEC-102
radiolabeled murine anti-CD20
RG-105
RHCACD20MA
RITUXAN
RITUXIMAB
rituximab-abbs
rituximab-arrx
rituximab-pvvr
SAIT101
SAIT-101
Zevalin
|
|
| 16 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
|
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
| 17 |
|
Lipoic acid |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
1200-22-2 |
864 6112 |
|
Synonyms:
(+)-a-Lipoate
(+)-a-Lipoic acid
(+)-alpha-Lipoate
(+)-alpha-Lipoic acid
(+)-α-lipoate
(+)-α-lipoic acid
(3R)-1,2-Dithiolane-3-pentanoic acid
(R)-(+)-1,2-Dithiolane-3-pentanoic acid
(R)-(+)-alpha-Lipoic acid
(R)-(+)-Lipoate
(R)-(+)-Lipoic acid
(R)-(+)-α-Lipoic acid
(R)-1,2-Dithiolane-3-pentanoate
(R)-1,2-Dithiolane-3-pentanoic acid
(R)-1,2-Dithiolane-3-valerate
(R)-1,2-Dithiolane-3-valeric acid
(R)-5-(1,2-Dithiolan-3-yl)pentanoicacid
(R)-6,8-Thioctate
(R)-6,8-Thioctic acid
(R)-alpha-Lipoic acid
(R)-Lipoate
(R)-Lipoic acid
(R)-α-Lipoic acid
1,2-Dithiolane-3-pentanoate
1,2-Dithiolane-3-pentanoic acid
1,2-Dithiolane-3R-pentanoate
1,2-Dithiolane-3R-pentanoic acid
1,2-Dithiolane-3-valerate
1,2-Dithiolane-3-valeric acid
5-(1,2-Dithiolan-3-yl)pentanoic acid
5-(1,2-Dithiolan-3-yl)valerate
5-(1,2-Dithiolan-3-yl)valeric acid
5-(3-DITHIOLANYL)PENTANOIC ACID
5-(DITHIOLAN-3-YL)PENTANOIC ACID
5-(Dithiolan-3-yl)valerate
5-(Dithiolan-3-yl)valeric acid
5-[3-(1,2-Dithiolanyl)]pentanoate
5-[3-(1,2-Dithiolanyl)]pentanoic acid
6,8-Thioctate
6,8-Thioctic acid
6,8-Thiotate
6,8-Thiotic acid
6-Thioctate
6-Thioctic acid
6-Thiotate
6-Thiotic acid
Acetate-replacing factor
Acetic acid-replacing factor
Acid, alpha-lipoic
ALA
a-Lipoate
a-Lipoic acid
a-Liponsaeure
Aliud brand OF thioctic acid
Alpha Lipogamma
alpha Lipoic acid
Alpha Lipon stada
alpha Liponaure heumann
Alpha Liponsaure sofotec
alpha Liponsaure von CT
Alpha Lippon al
alpha Vibolex
alpha-(+)-Lipoic acid
Alphaflam
alpha-Lipoate
AlphaLipogamma
Alpha-Lipogamma
alpha-Lipoic acid
AlphaLipon stada
Alpha-Lipon stada
alpha-Liponaure heumann
AlphaLiponaure heumann
alpha-Liponsaeure
ALPHA-LIPONSÄURE
AlphaLiponsaure sofotec
Alpha-Liponsaure sofotec
alpha-Liponsaure von CT
AlphaLiponsaure von CT
AlphaLippon al
Alpha-Lippon al
alpha-Vibolex
AlphaVibolex
Azulipont
Azupharma brand OF thioctic acid
Biletan
biomo Brand OF thioctic acid
Biomo lipon
Biomolipon
Biomo-lipon
CT Arzneimittel brand OF thioctic acid
CT-Arzneimittel brand OF thioctic acid
|
DL-a-Lipoate
DL-a-Lipoic acid
DL-alpha-Lipoate
DL-alpha-Lipoic acid
DL-Thioctate
DL-Thioctic acid
DL-Α-lipoate
DL-Α-lipoic acid
D-thioctic acid
Duralipon
Espa lipon
Espalipon
Espa-lipon
Esparma brand OF thioctic acid
Fenint
Generosan brand OF thioctic acid
Heumann brand OF thioctic acid
Hexal brand OF thioctic acid
Illa brand OF thioctic acid
Illa brand OF thioctic acid tromethamine
Injekt, thiogamma
Juta brand OF thioctic acid
Juthiac
Lichtenstein brand OF thioctic acid
Lipoate
Lipoic acid
LIPOIC ACID, ALPHA
Liponate
Liponic acid
Liponsaure ratiopharm
Liponsaureratiopharm
Liponsaure-ratiopharm
Merck dura brand OF thioctic acid
MTW Alphaliponsaure
MTW Brand OF thioctic acid
MTWAlphaliponsaure
MTW-Alphaliponsaure
Neurium
NSC-628502
NSC-90788
Pharmacia brand OF thioctic acid
Pleomix Alpha
Pleomix Alpha N
PleomixAlpha
Pleomix-Alpha
PleomixAlpha N
Pleomix-Alpha N
Q Pharm brand OF thioctic acid
Q-Pharm brand OF thioctic acid
R-(+)-Lipoate
R-(+)-Lipoic acid
R-(+)-thioctic acid
R-alpha-lipoic acid
Ratiopharm brand OF thioctic acid
RLA
R-LA
Rosen brand OF thioctic acid
Sofotec brand OF thioctic acid
Stadapharm brand OF thioctic acid
Thioctacid
Thioctacide T
Thioctansaeure
THIOCTANSÄURE
Thioctate
Thioctate D-form
Thioctic acid
Thioctic acid D-form
THIOCTIC ACID DL-FORM
Thioctsaeure
THIOCTSÄURE
Thiogamma injekt
Thiogamma oral
Thioktsaeure
THIOKTSÄURE
Thiotomin
TIOCTIC ACID
Tromlipon
Trommsdorgg brand OF thioctic acid
Verla brand OF thioctic acid
Verla lipon
Verla-lipon
VerlaLipon
Viatris brand OF thioctic acid
Viatris brand OF thioctic acid tromethamine
Worwag brand OF thioctic acid
Worwag brand OF thioctic acid meglumine
α-(+)-Lipoic acid
Α-lipoate
Α-lipoic acid
Α-liponsaeure
|
|
| 18 |
|
Biotin |
Approved, Investigational, Nutraceutical |
Phase 2 |
|
58-85-5 |
253 171548 |
|
Synonyms:
(+)-Biotin
-(+)-Biotin
(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valerate
(+)-cis-Hexahydro-2-oxo-1H-thieno[3,4]imidazole-4-valeric acid
(+)-CIS-HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOLE-4-PENTANOIC ACID
(3AS,4S,6ar)-hexahydro-2-oxo-1H-thieno[3,4-D]imidazole-4-valerate
(3AS,4S,6ar)-hexahydro-2-oxo-1H-thieno[3,4-D]imidazole-4-valeric acid
1SWK
1SWN
1SWR
5-(2-Oxohexahydro-1H-thieno[3,4-D]imidazol-4-yl)pentanoate
5-(2-Oxohexahydro-1H-thieno[3,4-D]imidazol-4-yl)pentanoic acid
5-[(1R,5S,6S)-3-OXO-7-THIA-2,4-DIAZABICYCLO[3.3.0]OCT-6-YL]PENTANOIC ACID
5-[(3AS,4S,6AR)-2-OXO-HEXAHYDRO-1H-THIENO[3,4-D]IMIDAZOLIDIN-4-YL]PENTANOIC ACID
Biocur brand OF biotin
Biodermatin
Bioepiderm
Biokur
Bios H
Bios II
Biotin
BIOTIN 100
Biotin biocur brand
Biotin dermapharm brand
Biotin gelfert
Biotin hermes
Biotin hermes brand
Biotin medopharm brand
Biotin ratiopharm
Biotin ratiopharm brand
Biotin roche brand
Biotin simons brand
Biotin strathmann brand
Biotin ziethen brand
Biotina
Biotine
Biotine roche
Biotinratiopharm
Biotin-ratiopharm
Biotinum
cis-(+)-Tetrahydro-2-oxothieno[3,4]imidazoline-4-valerate
cis-(+)-Tetrahydro-2-oxothieno[3,4]imidazoline-4-valeric acid
cis-Hexahydro-2-oxo-1H-thieno(3,4)imidazole-4-valerate
cis-Hexahydro-2-oxo-1H-thieno(3,4)imidazole-4-valeric acid
cis-Tetrahydro-2-oxothieno(3,4-D)imidazoline-4-valerate
|
cis-Tetrahydro-2-oxothieno(3,4-D)imidazoline-4-valeric acid
Coenzyme R
D(+)-Biotin
D-(+)-Biotin
D-Biotin
D-Biotin factor S
Deacura
delta-(+)-Biotin
delta-Biotin
delta-Biotin factor S
Dermapharm brand OF biotin
E+b pharma brand OF biotin
Factor S
Factor S (vitamin)
Gabunat
Gelfert, biotin
H, Vitamin
Hermes brand OF biotin
Hermes, biotin
Hexahydro-2-oxo-[3as-(3aa,4b,6aa)]-1H-thieno[3,4-D]imidazole-4-pentanoate
Hexahydro-2-oxo-[3as-(3aa,4b,6aa)]-1H-thieno[3,4-D]imidazole-4-pentanoic acid
Hexahydro-2-oxo-[3as-(3alpha,4beta,6alpha)]-1H-thieno[3,4-D]imidazole-4-pentanoate
Hexahydro-2-oxo-[3as-(3alpha,4beta,6alpha)]-1H-thieno[3,4-D]imidazole-4-pentanoic acid
Hexahydro-2-oxo-1H-thieno(3,4-D)imidazole-4-pentanoate
Hexahydro-2-oxo-1H-thieno(3,4-D)imidazole-4-pentanoic acid
HEXAHYDRO-2-OXO-1H-THIENO[3,4-D]IMIDAZOLE-4-PENTANOIC ACID
Lutavit H2
MD-1003
Medea brand OF biotin sodium salt
Medebiotin
Medobiotin
Medopharm brand OF biotin
Meribin
NSC-63865
Ratiopharm brand OF biotin
Roche brand OF biotin
Roche, biotine
Rombellin
Rovimix H 2
Simons brand OF biotin
Strathmann brand OF biotin
Vitamin b7
Vitamin H
Vitamin-H
Ziethen brand OF biotin
|
|
| 19 |
|
D-Phenylalanine |
Approved, Experimental, Investigational, Nutraceutical |
Phase 2 |
|
63-91-2, 673-06-3 |
6140 71567 |
|
Synonyms:
(-)-beta-Phenylalanine
(6S)-Tetrahydrofolate
(6S)-Tetrahydrofolic acid
(6S)-THFA
(L)-Phenylalanine
(S)-(-)-Phenylalanine
(S)-2-Amino-3-phenylpropanoate
(S)-2-Amino-3-phenylpropanoic acid
(S)-2-Amino-3-phenylpropionate
(S)-2-AMINO-3-PHENYLPROPIONIC ACID
(S)-a-Amino-b-phenylpropionate
(S)-a-Amino-b-phenylpropionic acid
(S)-alpha-Aminobenzenepropanoate
(S)-alpha-Amino-benzenepropanoate
(S)-alpha-Aminobenzenepropanoic acid
(S)-alpha-Amino-benzenepropanoic acid
(S)-alpha-Amino-beta-phenylpropionate
(S)-ALPHA-AMINO-BETA-PHENYLPROPIONIC ACID
(S)-alpha-Aminohydrocinnamate
(S)-alpha-Aminohydrocinnamic acid
(S)-Phenylalanine
(S)-Α-amino-β-phenylpropionate
(S)-Α-amino-β-phenylpropionic acid
3-PHENYL-L-ALANINE
5,6,7,8-Tetrahydrofolate
5,6,7,8-Tetrahydrofolic acid
a-Amino-b-phenylpropionate
a-Amino-b-phenylpropionic acid
alpha-Amino-beta-phenylpropionate
alpha-Amino-beta-phenylpropionic acid
alpha-Aminohydrocinnamate
|
alpha-Aminohydrocinnamic acid
beta-Phenylalanine
beta-Phenyl-alpha-alanine
BETA-PHENYL-L-ALANINE
b-Phenyl-L-alanine
D-(+)-phenylalanine
DL-Phenylalanine
Endorphenyl
F
FEMA NO. 3585
Fenilalanina
L-2-Amino-3-phenylpropionate
L-2-Amino-3-phenylpropionic acid
L-Isomer phenylalanine
L-PHE
L-Phenylalanine
NSC-79477
PHE
Phenylalamine
Phenylalanin
Phenylalanine
Phenyl-alanine
Phenylalanine, L isomer
Phenylalanine, L-isomer
Phenylalaninum
Tetrahydrofolate
THF
Α-amino-β-phenylpropionate
Α-amino-β-phenylpropionic acid
Î’-PHENYL-L-ALANINE
|
|
| 20 |
|
Cortisone |
Experimental |
Phase 2 |
|
53-06-5 |
222786 |
|
Synonyms:
11-Dehydro-17-hydroxycorticosterone
17a,21-Dihydroxy-4-pregnene-3,11,20-trione
17alpha,21-Dihydroxy-4-pregnene-3,11,20-trione
17-Hydroxy-11-dehydrocorticosterone
17-Hydroxy-3,11,20-trioxopregn-4-en-21-yl acetate
17Α,21-dihydroxy-4-pregnene-3,11,20-trione
4-Pregnene-17a,21-diol-3,11,20-trione
4-Pregnene-17alpha,21-diol-3,11,20-trione
4-Pregnene-17α,21-diol-3,11,20-trione
Adreson
Andreson
Anusol HC
Balneol-HC
beta-HC
Colocort
Compound e
Corlin
Cortadren
Cortandren
Cortef
Cortef acetate
Cortisal
Cortisate
Cortison
Cortisona
CORTISONE
Cortisone acetate
Cortisonum
Cortistal
Cortivite
Cortogen
Cortone
Cortone acetate
Cortril
delta(4)-Pregnene-17a,21-diol-3,11,20-trione
|
Delta(4)-Pregnene-17alpha,21-diol-3,11,20-trione
Dermacort
Dricort
Flexicort
Florinef
Fludrocortisone acetate
Glycort
Hemsol-HC
Hi-cor
Incortin
Kendall'S compound
Kendall's compound e
Kortison
Locoid
Locoid lipocream
Micort-HC
Nogenic HC
NSC-9703
Orabase hca
Pandel
Pregn-4-en-17a,21-diol-3,11,20-trione
Pregn-4-en-17alpha,21-diol-3,11,20-trione
Pregn-4-en-17α,21-diol-3,11,20-trione
Prestwick_132
Reichstein fa
Reichstein's substance fa
Scheroson
Solu-cortef
Stie-cort
Texacort
Westcort
Wintersteiner's compound F
Δ(4)-pregnene-17a,21-diol-3,11,20-trione
Δ(4)-pregnene-17α,21-diol-3,11,20-trione
|
|
| 21 |
|
Autoantibodies |
|
Phase 2 |
|
|
|
| 22 |
|
Vitamins |
|
Phase 2 |
|
|
|
| 23 |
|
Alpha-lipoic Acid |
|
Phase 2 |
|
|
|
| 24 |
|
Folate |
|
Phase 2 |
|
|
|
| 25 |
|
Vitamin B9 |
|
Phase 2 |
|
|
|
| 26 |
|
Trace Elements |
|
Phase 2 |
|
|
|
| 27 |
|
Vitamin B Complex |
|
Phase 2 |
|
|
|
| 28 |
|
Antioxidants |
|
Phase 2 |
|
|
|
| 29 |
|
Micronutrients |
|
Phase 2 |
|
|
|
| 30 |
|
Protective Agents |
|
Phase 2 |
|
|
|
| 31 |
|
Vitamin B7 |
|
Phase 2 |
|
|
|
| 32 |
|
Thymoglobulin |
|
Phase 2 |
|
|
|
| 33 |
|
Antineoplastic Agents, Hormonal |
|
Phase 2 |
|
|
|
| 34 |
|
glucocorticoids |
|
Phase 2 |
|
|
|
| 35 |
|
Anti-Inflammatory Agents |
|
Phase 2 |
|
|
|
| 36 |
|
Antiviral Agents |
|
Phase 2 |
|
|
|
| 37 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
| 38 |
|
Etoposide phosphate |
|
Phase 2 |
|
|
16760419 |
|
Synonyms:
{4-[16-({7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-D][1,3]dioxin-6-yl}oxy)-12-oxo-4,6,13-trioxatetracyclo[7.7.0.0,.0,]hexadeca-1,3(7),8-trien-10-yl]-2,6-dimethoxyphenoxy}phosphonate
BMY-40481
ETOPOPHOS
ETOPOPHOS PRESERVATIVE FREE
|
ETOPOSIDE PHOSPHATE
Etoposide phosphoric acid
VP16
VP-16
|
|
| 39 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
| 40 |
|
Keratolytic Agents |
|
Phase 2 |
|
|
|
| 41 |
|
Nitrogen Mustard Compounds |
|
Phase 2 |
|
|
|
| 42 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
| 43 |
|
Antilymphocyte Serum |
|
Phase 2 |
|
|
|
| 44 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
| 45 |
|
Dermatologic Agents |
|
Phase 2 |
|
|
|
| 46 |
|
Antibodies, Monoclonal |
|
Phase 2 |
|
|
|
| 47 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
| 48 |
|
Complement System Proteins |
|
Phase 2 |
|
|
|
| 49 |
|
D-Alanine |
Experimental, Nutraceutical |
Phase 2 |
|
302-72-7, 338-69-2, 56-41-7 |
101757026 602 71080 5950 |
|
Synonyms:
(2R)-2-Aminopropanoate
(2R)-2-Aminopropanoic acid
(2R)-2-Aminopropionic acid
(2S)-2-Aminopropanoate
(2S)-2-AMINOPROPANOIC ACID
(a-D-Mannosyl)7-b-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
(R)-2-Aminopropanoate
(R)-2-Aminopropanoic acid
(R)-2-Aminopropionic acid
(R)-Alanine
(S)-(+)-Alanine
(S)-2-Aminopropanoate
(S)-2-Amino-propanoate
(S)-2-Amino-propanoic acid
(S)-2-AMINOPROPANOIC ACID
(S)-ALANINE
(Α-D-mannosyl)7-β-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform a (protein)
[<sup>14</sup>C]-alanine
[<sup>3</sup>H]-alanine
2-Aminopropanoate
2-Aminopropanoic acid
2-Aminopropionate
2-Aminopropionic acid
2-Ammoniopropanoate
2-Ammoniopropanoic acid
A
a-Alanine
a-Aminopropionate
a-Aminopropionic acid
Abufène
ALA
Alanin
Alanina
Alanine
Alanine doms-adrian brand
Alanine, L isomer
Alanine, L-isomer
Alaninum
alpha-Alanine
alpha-Aminopropanoate
alpha-Aminopropanoic acid
alpha-Aminopropionate
|
alpha-Aminopropionic acid
D(-)-a -Alanine
D-(-)-Alanine
D(-)-alpha-Alanine
D(-)-Α-alanine
D-2-Aminopropionate
D-2-Aminopropionic acid
D-a-Alanine
D-a-Aminopropionate
D-a-Aminopropionic acid
DAL
D-Ala
D-Alanin
D-ALANINE
D-alpha-Alanine
D-alpha-Aminopropionate
D-alpha-Aminopropionic acid
Doms adrian brand OF alanine
Doms-adrian brand OF alanine
D-Α-alanine
D-Α-aminopropionate
D-Α-aminopropionic acid
E639
Ellagate arabinoside
L Alanine
L-(+)-Alanine
L-2-Aminopropanoate
L-2-Aminopropanoic acid
L-2-Aminopropionate
L-2-AMINOPROPIONIC ACID
L-a-Alanine
L-a-Aminopropionate
L-a-Aminopropionic acid
L-ALA
L-Alanin
L-Alanine
L-ALPHA-ALANINE
L-alpha-Aminopropionate
L-alpha-Aminopropionic acid
L-Isomer alanine
L-Α-ALANINE
NSC-206315
|
|
| 50 |
|
Rozanolixizumab |
Investigational |
|
|
1584645-37-3 |
|
|
Synonyms:
CA170_01519.g57 IgG4P|UCB-7665|UCB7665
|
|
|
Interventional clinical trials:
(show all 48)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study |
Unknown status |
NCT02372149 |
Phase 4 |
10% intravenous immunoglobulin (IVIg);0.9% sodium chloride |
| 2 |
Randomized, Parallel Study of Subcutaneous Versus Intravenous Immunoglobulin in Treatment-naïve Patients With Chronic Inflammatory Demyelinating Polyneuropathy |
Recruiting |
NCT04589299 |
Phase 4 |
|
| 3 |
Randomized Study of Two Dose Levels of Privigen in Pediatric CIDP |
Recruiting |
NCT03684018 |
Phase 4 |
|
| 4 |
Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates |
Unknown status |
NCT03166527 |
Phase 3 |
Immune Globulin 10% Intravenous Solution |
| 5 |
Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003 |
Completed |
NCT02027701 |
Phase 3 |
|
| 6 |
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy |
Completed |
NCT00004772 |
Phase 3 |
Immune globulin |
| 7 |
Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of IGIV-Chromatography (IGIV-C), 10% Treatment in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy |
Completed |
NCT00220740 |
Phase 3 |
Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP) |
| 8 |
Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy |
Completed |
NCT00004939 |
Phase 3 |
,4-diaminopyridine |
| 9 |
Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study |
Completed |
NCT01545076 |
Phase 3 |
|
| 10 |
Multicentre Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg in Patients With Chronic Inflammatory Demyelinating Polyneuropathy on a One Year Follow up |
Completed |
NCT01349270 |
Phase 3 |
Immunoglobulin perfusion;Prednisone |
| 11 |
NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy. |
Completed |
NCT01824251 |
Phase 3 |
NPB-01 |
| 12 |
A Single-arm Study to Demonstrate the Efficacy and Safety of Privigen in the Treatment of Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Completed |
NCT01184846 |
Phase 3 |
|
| 13 |
Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Recruiting |
NCT05327114 |
Phase 2, Phase 3 |
Nipocalimab;Placebo |
| 14 |
Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients |
Not yet recruiting |
NCT04929236 |
Phase 3 |
Panzyga |
| 15 |
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients With Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical Trial |
Completed |
NCT03864185 |
Phase 2 |
|
| 16 |
The Efficacy of High-Dose Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Completed |
NCT00001287 |
Phase 2 |
intravenous immunoglobulin (IVIg) |
| 17 |
Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study |
Completed |
NCT00962429 |
Phase 2 |
lipoic acid |
| 18 |
Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Trial |
Completed |
NCT00278629 |
Phase 2 |
|
| 19 |
SERENDEM Study: MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study |
Completed |
NCT02967679 |
Phase 2 |
MD1003 |
| 20 |
A Phase 2, Multicenter, Open-label, Non-randomized, Proof-of-concept Study Evaluating the Efficacy, Safety, and Tolerability of SAR445088 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Recruiting |
NCT04658472 |
Phase 2 |
SAR445088 (IV);SAR445088 (SC) |
| 21 |
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Recruiting |
NCT04280718 |
Phase 2 |
|
| 22 |
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Recruiting |
NCT04281472 |
Phase 2 |
|
| 23 |
High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases |
Recruiting |
NCT00716066 |
Phase 2 |
Carmustine;Cytarabine;Etoposide;Melphalan;Prednisone |
| 24 |
A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants With Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Not yet recruiting |
NCT05581199 |
Phase 2 |
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly;Batoclimab 340 mg SC weekly;Placebo |
| 25 |
Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase II Study |
Not yet recruiting |
NCT04480450 |
Phase 2 |
Rituximab |
| 26 |
Immunoadsorption Versus Immunoglobulins for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Not yet recruiting |
NCT04881682 |
Phase 2 |
|
| 27 |
A Phase II Trial of High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy |
Withdrawn |
NCT01236456 |
Phase 2 |
Cyclophosphamide |
| 28 |
Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy |
Withdrawn |
NCT02574962 |
Phase 2 |
H.P. Acthar® Gel |
| 29 |
The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration |
Recruiting |
NCT05584631 |
Phase 1 |
Intravenous immune globulin G;Subcutaneous immune globulin G |
| 30 |
sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid |
Unknown status |
NCT02271724 |
|
|
| 31 |
Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies |
Unknown status |
NCT03397303 |
|
|
| 32 |
Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG |
Completed |
NCT03008733 |
|
|
| 33 |
Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN) |
Completed |
NCT02121678 |
|
|
| 34 |
A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy |
Completed |
NCT02465359 |
|
Immune Globulin Subcutaneous (Human) |
| 35 |
Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER) |
Completed |
NCT02414490 |
|
Intravenous Immunoglobulin |
| 36 |
Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy |
Completed |
NCT01379833 |
|
|
| 37 |
The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN |
Completed |
NCT02111590 |
|
Immunoglobulins |
| 38 |
Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
Recruiting |
NCT03772717 |
|
|
| 39 |
Evaluation of the Diagnostic Contributions of Nerve Ultrasound in Chronic Inflammatory Demyelinating Polyneuropathy Associating Systemic Diseases |
Recruiting |
NCT05257733 |
|
|
| 40 |
A Registered Cohort Study of Immune-Mediated Neuropathies |
Recruiting |
NCT04292834 |
|
|
| 41 |
A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives |
Recruiting |
NCT01931644 |
|
|
| 42 |
Hizentra® in Inflammatory Neuropathies - pHeNIx Study |
Recruiting |
NCT04672733 |
|
|
| 43 |
Correlation of Circulating NT-3 Levels and Function in Individuals With Peripheral Neuropathy or Charcot-Marie-Tooth Neuropathy |
Recruiting |
NCT05011006 |
|
|
| 44 |
CIDP07 Rozanolixizumab Post Trial Access Program (the PTA) |
Available |
NCT05014724 |
|
Rozanolixizumab |
| 45 |
Study of Connected Soles With Pressure Sensors in the Evaluation of Gait Disorders in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). |
Not yet recruiting |
NCT05492604 |
|
|
| 46 |
Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy Among Patients Attending Neuropsychiatry Department - Assiut University |
Not yet recruiting |
NCT05219383 |
|
|
| 47 |
An Expanded Access IND to Evaluate the Safety and Preliminary Efficacy of Autologous HB-adMSCs for the Treatment of a Single Patient With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) |
No longer available |
NCT04825626 |
|
|
| 48 |
A Multicenter Pilot Study to Determine Criteria for Evaluating the Effectiveness of Two Comparative Monitoring Methods in the Management of Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Receiving Home-based Treatment With IVIg (Privigen®) |
Terminated |
NCT03779828 |
|
|
|
